Annals of plastic surgery · 2025
Primary Cutaneous Follicle Center Lymphoma: Demographic, Socioeconomic, and Clinical Prognostic Factors in a National Cohort.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Taghizadeh Catherine S, Toromani Gejla, Hsia Beau, Rafie Susan, Barrera Angela, Kalmar Christopher L
Аннотация
PURPOSE: Primary cutaneous follicle center lymphoma (PCFCL) is a rare form of indolent B-cell lymphoma limited to the skin. This study aims to explore various factors affecting overall survival in patients with PCFCL using data from the National Cancer Database.
METHODS: Patients with PCFCL were identified in the National Cancer Database between 2004 and 2020 using the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histology code 9597. Time-to-event outcomes were analyzed with the Kaplan-Meier method, log-rank tests, and multivariable Cox hazard regression models to understand the association of demographic and prognostic factors on survival in patients with PCFCL.
RESULTS: During the study interval, 1293 patients were identified with PCFCL, of which 64% were male, 50% were Stage I, and 84% had a Charlson-Deyo (CD) comorbidity score of 0. Key factors associated with worse overall survival included lower income ( P = 0.030), nonprivate insurance ( P < 0.001), and lower education levels ( P = 0.015). Additionally, female sex ( P = 0.014), older age ( P < 0.001), higher CD scores ( P < 0.001), stage II ( P = 0.013), stage III ( P = 0.003), and lack of primary radiation therapy ( P = 0.047) were associated with lower survival. Multivariate analysis confirmed that elevated comorbidity index [hazard ratio (HR) = 5.96, 95% confidence interval (CI): 2.82-12.59, P < 0.001], older age (HR = 1.57, 95% CI: 1.41-1.74, P < 0.001), and higher disease stage (Stage I vs II: HR = 2.15, 95% CI: 1.07-4.29, P = 0.031) were significantly associated with lower survival.
CONCLUSIONS: In patients with PCFCL, female sex, older age, higher comorbidity index, higher disease stage, lower income, nonprivate insurance, and lower education levels were associated with lower overall survival.
METHODS: Patients with PCFCL were identified in the National Cancer Database between 2004 and 2020 using the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histology code 9597. Time-to-event outcomes were analyzed with the Kaplan-Meier method, log-rank tests, and multivariable Cox hazard regression models to understand the association of demographic and prognostic factors on survival in patients with PCFCL.
RESULTS: During the study interval, 1293 patients were identified with PCFCL, of which 64% were male, 50% were Stage I, and 84% had a Charlson-Deyo (CD) comorbidity score of 0. Key factors associated with worse overall survival included lower income ( P = 0.030), nonprivate insurance ( P < 0.001), and lower education levels ( P = 0.015). Additionally, female sex ( P = 0.014), older age ( P < 0.001), higher CD scores ( P < 0.001), stage II ( P = 0.013), stage III ( P = 0.003), and lack of primary radiation therapy ( P = 0.047) were associated with lower survival. Multivariate analysis confirmed that elevated comorbidity index [hazard ratio (HR) = 5.96, 95% confidence interval (CI): 2.82-12.59, P < 0.001], older age (HR = 1.57, 95% CI: 1.41-1.74, P < 0.001), and higher disease stage (Stage I vs II: HR = 2.15, 95% CI: 1.07-4.29, P = 0.031) were significantly associated with lower survival.
CONCLUSIONS: In patients with PCFCL, female sex, older age, higher comorbidity index, higher disease stage, lower income, nonprivate insurance, and lower education levels were associated with lower overall survival.